Skip to content

Study · Not a test of the peptide alone · 1998

4 results

[Immunotherapy of pulmonary tuberculosis].

Khudzik LB, Salina TIu, Parolina LE

Problemy tuberkuleza1 Jan 1998Cited by 1 (Europe PMC)

PMID10067345 (opens in a new tab)PepBankPUB-10067345
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In destructive tuberculosis, immunocorrector treatment including thymalin produced early benefit during complex therapy.

    In plain wordsIn destructive tuberculosis patients, immunocorrector treatments including thymalin produced early benefit during combined treatment.

    Peptide
    Thymalin
    Outcome
    IncreaseEarly treatment benefit
    Study

    n = 553

    Outcome group
    Infection and antimicrobial activity · Respiratory

    Source sentences

    Summary
    The benefit from immunocorrector treatment was obtained early in the complex therapy
    2 context sentences
    Summary · context
    The efficiency of treating patients with destructive tuberculosis by using different immune correctors was comparatively analyzed.
    Summary · context
    Five hundred and fifty three patients were treated with thymalin, thymogen, human leukocytic interferon, and a combination of thymogen and interferon.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  2. 02HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In patients with destructive tuberculosis, immunocorrector regimens including thymogen provided early benefit during complex therapy.

    In plain wordsIn patients with tuberculosis, regimens including thymogen showed early treatment benefit.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseEarly treatment benefit
    Study

    n = 553

    Destructive pulmonary tuberculosis
    Outcome group
    Infection and antimicrobial activity · Respiratory

    Source sentences

    Summary
    The benefit from immunocorrector treatment was obtained early in the complex therapy and the best result was achieved by the use of thymogen plus interferon.
    2 context sentences
    Summary · context
    The efficiency of treating patients with destructive tuberculosis by using different immune correctors was comparatively analyzed.
    Summary · context
    Five hundred and fifty three patients were treated with thymalin, thymogen, human leukocytic interferon, and a combination of thymogen and interferon.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  3. 03HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In destructive tuberculosis, thymogen plus interferon produced the best reported result among the tested immunocorrector regimens.

    In plain wordsIn patients with tuberculosis, thymogen plus interferon gave the best result among the tested regimens.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseComparative treatment result
    Study

    n: not reported in source

    Destructive pulmonary tuberculosis
    Comparator
    Other tested immunocorrector regimens
    Outcome group
    Infection and antimicrobial activity · Respiratory

    Source sentences

    Summary
    The benefit from immunocorrector treatment was obtained early in the complex therapy and the best result was achieved by the use of thymogen plus interferon.
    2 context sentences
    Summary · context
    The efficiency of treating patients with destructive tuberculosis by using different immune correctors was comparatively analyzed.
    Summary · context
    Five hundred and fifty three patients were treated with thymalin, thymogen, human leukocytic interferon, and a combination of thymogen and interferon.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

  4. 04HumanNot a test of Thymogen (oglufanide) aloneNon-randomized trialEfficacy outcome

    In patients with destructive tuberculosis, the action of the two immunocorrectors increased once fibrous lung deformity healed.

    In plain wordsIn patients with tuberculosis, the two immunocorrectors showed increased action as fibrous lung deformity healed.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseTreatment action during healing of fibrous lung deformity
    Study

    n: not reported in source

    Destructive pulmonary tuberculosis
    Outcome group
    Infection and antimicrobial activity · Respiratory

    Source sentences

    Summary
    However, the action of the two immunocorrectors increased when fibrous deformity of the lung was healed, followed by the development of pronounced residual changes.
    2 context sentences
    Summary · context
    The efficiency of treating patients with destructive tuberculosis by using different immune correctors was comparatively analyzed.
    Summary · context
    Five hundred and fifty three patients were treated with thymalin, thymogen, human leukocytic interferon, and a combination of thymogen and interferon.

    In this study, Thymogen (oglufanide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymogen (oglufanide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 12:50 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    14 Oct 2026, 05:02 UTC

    Study results updated

  3. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.